Biotech RadarJobs updated

COMPANY

SURGE Therapeutics

HQ: Cambridge, MA source · surgetx.com ↗

Clinical Phase 3

Keywords: hydrogel TNBC - Triple-Negative Breast Cancer Breast Cancer Non-muscle-invasive Bladder Cancer Prostate Cancer SRG-514 STM-416 STM-416p

Location: Cambridge, MA · source · Jun 2, 2023

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start 3: Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery source ↗
  2. Trial start Phase 1: Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy source ↗
  3. Trial start Phase 1: SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery source ↗
  4. Trial start Phase 1/Phase 2: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07723469Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery3Not yet recruiting2026-102034-10 (estimated)
NCT06300411SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer SurgeryPhase 1CompletedJul 29, 2024Apr 8, 2026 (actual)
NCT05710848A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder CancerPhase 1/Phase 2RecruitingJul 11, 20232026-05 (estimated)
NCT06450106Study of STM-416p Administered to Patients Undergoing Radical ProstatectomyPhase 1RecruitingMay 8, 20252026-09 (estimated)
Feedback